Dovitinib has already shown antitumor activity in FGFR-amplified BC cell lines in preclinical models, and in a phase II trial recruiting patients with metastatic BC with and without FGFR1 amplification, dovitinib showed increased activity in BC with FGF pathway amplification. The gene discussed is FGFR1; the disease is breast cancer.